EMPOWERing the Next Generation

News
Article

An expert discusses recent research evaluating a selective M4 positive allosteric modulator for the treatment of schizophrenia.

CONFERENCE REPORTER

Erica Koenig, PhD, gives an overview of Cerevel Therapeutics and discusses EMPOWER, a phase 2 clinical trial evaluating emraclidine for the treatment of schizophrenia. Koenig presented this research in a poster presentation at Psych Congress 2023.

Dr Koenig is program lead of emraclidine and senior director of global clinical development at Cerevel Therapeutics.

Related Videos
ADHD
suicide prevention
depression
exciting, brain
treatment resistant depression
writing
stop violence
together
© 2024 MJH Life Sciences

All rights reserved.